Ca(NTf
<sub>2</sub>
)
<sub>2</sub>
/HFIP‐Mediated Direct and Mild Rearrangement of Cyclopropyl Carbinols to
<i>E</i>
‐Homoallylic Triflimides
作者:Min Wu、Zhiqiang Duan、Qingmei Liu、Hui Gao、Zhi Zhou、Wei Yi、Shengdong Wang
DOI:10.1002/ejoc.202200813
日期:2022.9.27
A novel, general and straightforward Ca(NTf2)2/HFIP-mediated rearrangement of cyclopropyl carbinols for the construction of E-homoallylic triflimides has been developed. In this protocol, Ca(NTf2)2 was used as both the OH activator and the triflimide anion source. This transformation takes place under mild conditions and shows an impressive substrate and functional group tolerance.
cyclopropyl-substituted ACPs with B2pin2 and acidchlorides has been developed. Using cyclopropyl-substituted ACPs as the starting material, a broad range of 1,5-boroacylated products with multiple functional groups was prepared in good yields with excellent regio- and stereoselectively. Both aromatic and aliphaticacidchlorides were tolerated in this reaction.
DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:US20180148453A1
公开(公告)日:2018-05-31
The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.